Abstract
The recognition that uric acid plays a significant role in cardiac function has been slow to be appreciated. About 50 years ago it was recognized that gout and high uric acid levels were often a marker for coronary heart disease, Since then the literature has contained several hundred studies which have demonstrated a great deal of the physiology of xanthine oxidase inhibition. A reduction in xanthine oxidase improves cardiac output, improves endothelial function, reduces myocardial infarct size, reduces inflammation, reduces myocardial oxidative stress and platelet adhesiveness. It seems logical that these effects would be beneficial to patients with congestive heart failure. A large placebo controlled trial with Allopurinol seems very likely to demonstrate that this old fashioned drug provides a new found benefit.
Keywords: Allopurinol, congestive heart failure, oxypurinol, oxygen consumption, hypoxanthine
Cardiovascular & Hematological Disorders-Drug Targets
Title: Xanthine Oxidase Inhibitors the Unappreciated Treatment for Heart Failure
Volume: 7 Issue: 4
Author(s): Myrvin H. Ellestad
Affiliation:
Keywords: Allopurinol, congestive heart failure, oxypurinol, oxygen consumption, hypoxanthine
Abstract: The recognition that uric acid plays a significant role in cardiac function has been slow to be appreciated. About 50 years ago it was recognized that gout and high uric acid levels were often a marker for coronary heart disease, Since then the literature has contained several hundred studies which have demonstrated a great deal of the physiology of xanthine oxidase inhibition. A reduction in xanthine oxidase improves cardiac output, improves endothelial function, reduces myocardial infarct size, reduces inflammation, reduces myocardial oxidative stress and platelet adhesiveness. It seems logical that these effects would be beneficial to patients with congestive heart failure. A large placebo controlled trial with Allopurinol seems very likely to demonstrate that this old fashioned drug provides a new found benefit.
Export Options
About this article
Cite this article as:
Ellestad H. Myrvin, Xanthine Oxidase Inhibitors the Unappreciated Treatment for Heart Failure, Cardiovascular & Hematological Disorders-Drug Targets 2007; 7 (4) . https://dx.doi.org/10.2174/187152907782793563
DOI https://dx.doi.org/10.2174/187152907782793563 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Associations between Alzheimer’s Disease and Blood Homocysteine, Vitamin B<sub>12</sub>, and Folate: A Case-Control Study
Current Alzheimer Research Vitamin Bs, One Carbon Metabolism and Prostate Cancer
Mini-Reviews in Medicinal Chemistry Medicinal Chemistry of ATP Synthase: A Potential Drug Target of Dietary Polyphenols and Amphibian Antimicrobial Peptides
Current Medicinal Chemistry Recent Developments in Phytosterol Recovery from Oil Deodorizer Distillates
Current Nutrition & Food Science Combining Diffusion-Weighted Imaging Patterns with ABCD2 Score Predicts Stroke Risk after Transient Ischemic Attack
Current Neurovascular Research Gene Therapy for Familial Hypercholesterolemia
Current Pharmaceutical Design Role of Sulfur Containing Amino Acids as an Adjuvant Therapy in the Prevention of Diabetes and its Associated Complications
Current Diabetes Reviews Rational Basis for Nutraceuticals in the Treatment of Glaucoma
Current Neuropharmacology Auto-Antibodies As Possible Markers and Mediators of Ischemic, Dilated, and Rhythmic Cardiopathies
Current Drug Targets A Review of the Characteristics, Properties and Methods for Quantification of Roxithromycin
Current Pharmaceutical Analysis Atrial Tachycardias Occurring Late After Open Heart Surgery
Current Cardiology Reviews Meet Our Section Editor
Current Diabetes Reviews Management of the Menopausal Disturbances and Oxidative Stress
Current Pharmaceutical Design Noncoding Variants Functional Prioritization Methods Based on Predicted Regulatory Factor Binding Sites
Current Genomics Potential Role of Polyphenols in the Prevention of Cardiovascular Diseases: Molecular Bases
Current Medicinal Chemistry Adherence to Secondary Prophylaxis Among Patients with Acute Rheumatic Fever and Rheumatic Heart Disease
Current Cardiology Reviews Clinical Value of Prostacyclin and its Analogs in the Management of Pulmonary Arterial Hypertension
Current Vascular Pharmacology Preoperative and Follow up Multi-Detector Row CT Angiography (MDCTA) in the Evaluation of Interrupted Aortic Arch (IAA)
Current Medical Imaging Carvedilol: Just Another Beta-Blocker or a Powerful Cardioprotector?
Cardiovascular & Hematological Disorders-Drug Targets 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitors as Promising Therapeutic Drugs for Diabetes: Status and Development
Current Medicinal Chemistry